LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback